abstract |
The present technology relates to a pharmaceutical composition containing Leuc-a for the treatment of retinal vein occlusion. The fibrinolytic enzyme, Leuc-a, can be administered in the form of an aqueous solution by intravitreal injection, as a new alternative for the treatment of retinal vein occlusion (RVO). |